Diabetic population mortality and cardiovascular risk attributable to hypertension: A decade follow-up from the Tehran Lipid and Glucose Study

References

• Safran MA, Vinicor F. The war against diabetes. How will we know if we are winning? Diabetes Care. 1999;22:508–516.
   PubMed Web of Science ®Google Scholar
• Fox CS, Coady S, Sorlie PD, D’Agostino RB, Sr., Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation. 2007;115:1544–1550.
   PubMed Web of Science ®Google Scholar
• Bozorgmanesh M, Hadaegh F, Sheikholeslami F, Azizi F. Cardiovascular risk and all cause mortality attributable to diabetes: Tehran Lipid and Glucose Study. J Endocrinol Invest. 2012;35:14–20.
   PubMedGoogle Scholar
• Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension. 2001;37:1053–1059.
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 1998; 316:823–828.
   PubMed Web of Science ®Google Scholar
• Hypertension in Diabetes Study (HDS): II. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients: The Hypertension in Diabetes Study Group.J Hypertens. 1993;11:319–325.
   PubMed Web of Science ®Google Scholar
• Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NRC. Cardiovascular outcomes in Framingham participants with diabetes. Hypertension. 2011;57:891–897.
   PubMed Web of Science ®Google Scholar
• Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5.
   PubMed Web of Science ®Google Scholar
• Freedman DS, Kahn HS, Mei Z, Grummer-Strawn LM, Dietz WH, Srinivasan SR, et al. Relation of body mass index and waist-to-height ratio to cardiovascular disease risk factors in children and adolescents: The Bogalusa Heart Study. Am J Clin Nutr. 2007;86:33–40.
   PubMed Web of Science ®Google Scholar
• Hadaegh F, Harati H, Ghanbarian A, Azizi F. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Eur J Cardiovasc Prev Rehabil. 2006;13:571–577.
   PubMedGoogle Scholar
• Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).Circulation. 2003;107: 149–158.
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction –2002: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).Circulation.2002;106:1893–1900.
   PubMed Web of Science ®Google Scholar
• Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC, Jr., Havas S, et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: A report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): Developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research.Circulation. 2009;120:1296–1336.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL,Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560–2572.
   PubMed Web of Science ®Google Scholar
• Chen YQ, Hu C, Wang Y. Attributable risk function in the proportional hazards model for censored time-to-event. Biostatistics. 2006;7:515.
   PubMed Web of Science ®Google Scholar
• Samuelsen SO, Eide GE. Attributable fractions with survival data. Stat Med. 2008;27:1447–1467.
   PubMedGoogle Scholar
• Silverberg MJ, Smith MW, Chmiel JS, Detels R, Margolick JB, Rinaldo CR, et al. Fraction of cases of acquired immunodeficiency syndrome prevented by the interactions of identified restriction gene variants. Am J Epidemiol. 2004; 159:232–241.
   PubMedGoogle Scholar
• Laaksonen MA, Knekt P, Härkänen T, Virtala E, Oja H. Estimation of the population attributable fraction for mortality in a cohort study using a piecewise constant hazards model. Am J Epidemiol. 2010;171:837–847.
   PubMedGoogle Scholar
• Levin ML. The occurrence of lung cancer in man. Acta – Unio Internationalis Contra Cancrum. 1953;9:531–541.
   PubMedGoogle Scholar
• Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Circulation. 2007;115: 114–126.
   PubMed Web of Science ®Google Scholar
• Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ. 2011; 343:d4169.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. JAMA. 2002;287:2570–2581.
   PubMed Web of Science ®Google Scholar
• Søren Christensen, Kjærgaard H-HTH, Lars Fog, Inge Bülow, Per Dahl Christensen. In-hospital outcome for diabetic patients with acute myocardial infarction in the thrombolytic era. Scand Cardiovasc J. 1999;33:166–170.
   PubMedGoogle Scholar
• Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-Wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014–1019.
   PubMed Web of Science ®Google Scholar
• Zuanetti G, Latini R, Maggioni A, Santoro L, Franzosi M. Influence of diabetes on mortality in acute myocardial infarction: Data from the GISSI-2 study. J Am Coll Cardiol. 1993;22:1788–1794.
   PubMed Web of Science ®Google Scholar
• Shindler DM, Palmeri ST, Antonelli TA, Sleeper LA, Boland J, Cocke TP, et al. Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK Trial Registry. J Am Coll Cardiol. 2000;36(3_Suppl_A):1097–1103.
   PubMedGoogle Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917–932.
   PubMed Web of Science ®Google Scholar
• Narayan KMV, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884–1890.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes—2013. Diabetes Care.2013;36 Supplement 1:S11–S66.
   PubMed Web of Science ®Google Scholar
• Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Intensive glycaemic control for patients with type 2 diabetes: Systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898.
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. The Lancet. 2009;373:1765–1772.
   PubMed Web of Science ®Google Scholar
• Conget I, Giménez M. Glucose control and cardiovascular disease. Diabetes Care. 2009;32 Suppl 2:S334–S336.
   Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. The Lancet. 2000;355:253–259.
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GEHM, Sandbæk A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): A cluster-randomised trial. The Lancet. 2011; 378:156–167.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713–720.
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677–684.
   PubMed Web of Science ®Google Scholar
• Samadi S, Bozorgmanesh M, Khalili D, Momenan A, Sheikholeslami F, Azizi F, et al. Hypertriglyceridemic waist: The point of divergence for prediction of CVD vs. mortality: Tehran Lipid and Glucose Study. Int J Cardiol. 2011 Sep 15 [Epub ahead of print].
   Google Scholar
• Hamid Zargar A, Iqbal Wani A, Rashid Masoodi S, Ahmad Laway B, Iftikhar Bashir M. Mortality in diabetes mellitus – Data from a developing region of the world. Diabetes Res Clin Pract. 1999;43:67–74.
   PubMedGoogle Scholar
• Wong JSK, Pearson DWM, Murchison LE, Williams MJ, Narayan V. Mortality in diabetes mellitus: Experience of a geographically defined population. Diabetic Med. 1991;8: 135–139.
   PubMed Web of Science ®Google Scholar
• Mirmiran P, Ramezankhani A, Hekmatdoost A, Azizi F. Effect of nutrition intervention on non-communicable disease risk factors among Tehranian adults: Tehran Lipid and Glucose Study. Ann Nutr Metab. 2008;52:91–95.
   PubMedGoogle Scholar
• Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, et al. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am J Prev Med. 2010;38:628–636.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc Ser B. 1995:289–300.
   Google Scholar
• O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979:549–556.
   Google Scholar
• Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Statist. 2001:1165–1188.
   Google Scholar
• Heller RF, Dobson AJ, Attia J, Page J. Impact numbers: Measures of risk factor impact on the whole population from case-control and cohort studies. J Epidemiol Community Health. 2002;56:606–610.
   PubMedGoogle Scholar
• Walter SD. Calculation of attributable risks from epidemiological data. Int J Epidemiol. 1978;7:175–182.
   PubMed Web of Science ®Google Scholar
• Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med Res. 2001;10:195–216.
   PubMed Web of Science ®Google Scholar
• Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health. 1998;88: 15–19.
   PubMed Web of Science ®Google Scholar